Trump Signs Order on Psychedelics to Ease FDA Restrictions (1)

April 18, 2026, 4:16 PM UTC

President Donald Trump signed an executive order to expedite research and access to psychedelics used outside the US to treat post-traumatic stress disorder.

“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said in an Oval Office ceremony Saturday.

The order directs the US Food and Drug Administration to issue new guidance to researchers on ibogaine, a psychedelic compound extracted from the iboga plant in Africa that’s used to treat depression, anxiety and PTSD for military veterans. The hallucinogen is considered a Schedule I ...

Learn more about Bloomberg Tax or Log In to keep reading:

See Breaking News in Context

From research to software to news, find what you need to stay ahead.

Already a subscriber?

Log in to keep reading or access research tools and resources.